 |
Case Report
Can immunization against SARS-CoV-2 be the triggering factor for seizures?
1 Master’s Program in Neurology, University of Vassouras and School of Medicine, University of Iguaçu, Nova Iguaçu, RJ, Brazil
2 Department of Neurology of Hospital Geral de Nova Iguaçu, Iguaçu University, UNIG, Nova Iguaçu, RJ, Brazil
3 Department of Neurology of Federal University of Rio de Janeiro, UFRJ, Rio de Janeiro, RJ, Brazil
4 Department of Medicine, UNIFESP, Paulista School of Medicine, São Paulo, SP, Brazil
Address correspondence to:
Antônio Marcos da Silva Catharino
Rua Gavião Peixoto 70, Room 811, CEP 24.2230-100, Icaraí, Niterói, RJ,
Brazil
Message to Corresponding Author
Article ID: 101364Z01MO2022
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Orsini M, da Silva Catharino AM, Silveira VC, Reis CHM, de Freitas MRG, de Oliveira AB. Can immunization against SARS-CoV-2 be the triggering factor for seizures? Int J Case Rep Images 2022;13(2):219–221.ABSTRACT
Introduction: Neurotropic and neuroinvasive tropism of coronaviruses have been described in humans. Neurological disorders reported in the current literature in patients with coronavirus infection include: febrile seizures, fatigue, cognitive impairment, asthenia, hyposmia, ageusia, seizures, loss of consciousness, encephalomyelitis and encephalitis, Guilain-Barré syndrome, optic neuritis, peripheral neuropathies, among others. In contrast, reports of epileptic seizures after immunization against SARS-CoV-2 are interrogated.
Case Report: We report the case of a 12-year-old student, healthy, without comorbidities, who, 22 hours after the second dose of an immunization against SARS-CoV-2, started the first seizure.
Conclusion: The time interval between vaccination and the outbreak of crises, we believe, should be taken into account in the present case; mainly because she was a healthy teenager, with no recent previous factors that could serve as triggers.
Keywords: Ad26.COV2-S, COVID-19, SARS-CoV-2, Seizures, Vaccine
SUPPORTING INFORMATION
Author Contributions
Marco Orsini - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Antônio Marcos da Silva Catharino - Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Valéria Camargo Silveira - Acquisition of data, Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Carlos Henrique Melo Reis - Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Marcos RG de Freitas - Acquisition of data, Analysis of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Acary Bulle de Oliveira - Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2022 Marco Orsini et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
